We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue

Snibe Diagnostic’s Maglumi HIV Ab/Ag Combi CLIA Assay (4th-Generation) Secures CE Mark (List A)

By LabMedica International staff writers
Posted on 16 Apr 2021
Print article
Image: Snibe Diagnostic’s Maglumi HIV Ab/Ag Combi CLIA Assay (4th-Generation) Secures CE Mark (List A) (Photo courtesy of Snibe Diagnostic)
Image: Snibe Diagnostic’s Maglumi HIV Ab/Ag Combi CLIA Assay (4th-Generation) Secures CE Mark (List A) (Photo courtesy of Snibe Diagnostic)
Snibe Diagnostic (Shenzhen, China) has received the CE certificate (List A) for the Maglumi HIV Ab/Ag Chemiluminescence Immunoassay (CLIA) assay.

CE List A is the highest level of CE certification, which requires that the entire product performance verification process needs to be independently completed in Europe by a third party, and the results also need to be compared with the excellent products of the EU. It indicates that Maglumi HIV Ab/Ag Combi CLIA kit has totally met EU standards of performance, quality and safety, and can be sold in European markets.

HIV, or the human immunodeficiency virus, remains a major global public health problem, killing nearly 33 million people to date. Early diagnosis plays an essential role in the effective treatment of HIV and in increasing the survival rate of HIV patients. In the early stage of infection, the infected person usually has no specific clinical manifestations, and the HIV cannot be detected by conventional antibody detection methods, resulting in further spread of the virus. Adopting effective methods to detect early-stage infections and providing intervention and treatment are of great significance to individual and public health.

The US CDC’s laboratory testing guideline reports that HIV-1 p24 antigen is expressed and quantities rise to a level that can be detected by 4th generation immunoassays within four to 10 days after the initial detection of HIV-1 RNA. Next, immunoglobulin (Ig) M antibodies are expressed which can be detected by 3rd and 4th generation immunoassays three to five days after p24 antigen is first detectable, 10 to 13 days after the appearance of viral RNA.

The Maglumi HIV Ab/Ag Combi CLIA assay is the 4th generation HIV assay, which can reduce the detection window period by detecting not only HIV-1/2 antibodies but also the p24 antigen. The assay has an excellent clinical performance validated by the third-party independent laboratory in Germany, including: 100% clinical sensitivity for the positive samples of HIV-1 p24, Anti-HIV-1 and Anti-HIV-2; 99.98% clinical specificity for blood donor samples; equal or more sensitive than most commercial assays in the seroconversion panels detection; analytical sensitivity of 0.7695 IU/mL when testing the NIBSC HIV-1 p24 antigen (NIBSC code: 90/636, ≤ 2.0 IU/mL); no cross-reaction with common potential interferent; validated different types of sample collecting tube; and capability to detect various groups of HIV.

Related Links:
Snibe Diagnostic
Gold Supplier
Streptococcus Test
STREPA’LERT
New
Sequencing System
NovaSeq 6000 Sequencing System
New
SARS-CoV-2 S1/S2 IgG Assay
LIAISON SARS-CoV-2 S1/S2 IgG
New
COVID-19 Antigen Rapid Test
CareStart COVID-19 Antigen Rapid Test

Print article
BIOHIT  Healthcare OY
Mayo Medical Laboratories

Channels

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.